Why is Bliss GVS Pharma falling/rising?

As of 22-Sep, Bliss GVS Pharma Ltd is experiencing a price increase, currently at 152.10, reflecting a change of 1.55 or 1.03% upward. Today's price summary indicates that the stock has outperformed its sector by 2.11%. The stock is trading higher than its 100-day and 200-day moving averages, although it is lower than the 5-day, 20-day, and 50-day moving averages. Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 60.71% compared to the 5-day average. Despite a year-to-date decline of 7.62%, the stock has generated a 17.27% return over the past year, although profits have decreased by 3.6%. The company maintains a low debt-to-equity ratio and a fair valuation, which may contribute to its recent positive movement.
In the broader market context, the stock's short-term performance has been slightly negative, with a 1-week return of -0.07%, while the Sensex has gained 0.46% in the same period. Over the past month, Bliss GVS Pharma has underperformed the benchmark, with a decline of 5.79% compared to the Sensex's increase of 1.05%. However, the stock has shown consistent returns over the last three years, outperforming the BSE500 annually. This long-term performance, combined with the recent uptick in trading activity and investor interest, suggests a potential recovery phase, despite the recent underperformance relative to the broader market.